Twist Bioscience Corporation (NASDAQ:TWST) Receives $46.50 Consensus Price Target from Analysts

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $46.50.

Several equities research analysts have recently weighed in on TWST shares. Barclays increased their price objective on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Guggenheim upped their target price on shares of Twist Bioscience from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, February 3rd. Finally, TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th.

Insider Activity

In related news, Director Robert Chess sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total transaction of $470,000.00. Following the transaction, the director directly owned 21,084 shares in the company, valued at $990,948. The trade was a 32.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam Laponis sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $50.00, for a total value of $350,000.00. Following the completion of the sale, the chief financial officer owned 130,031 shares of the company’s stock, valued at $6,501,550. This represents a 5.11% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 49,190 shares of company stock valued at $2,285,695. Corporate insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC increased its holdings in Twist Bioscience by 12.4% in the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after buying an additional 832,687 shares during the period. Artisan Partners Limited Partnership increased its stake in Twist Bioscience by 26.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after acquiring an additional 1,349,867 shares during the period. William Blair Investment Management LLC raised its position in Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after purchasing an additional 1,812,146 shares in the last quarter. EdgePoint Investment Group Inc. lifted its stake in Twist Bioscience by 31.7% during the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after purchasing an additional 1,295,672 shares during the period. Finally, State Street Corp boosted its holdings in Twist Bioscience by 17.4% during the fourth quarter. State Street Corp now owns 3,627,818 shares of the company’s stock valued at $115,074,000 after purchasing an additional 538,755 shares in the last quarter.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $50.21 on Friday. Twist Bioscience has a 52 week low of $23.30 and a 52 week high of $57.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The firm has a market capitalization of $3.08 billion, a PE ratio of -39.23 and a beta of 2.20. The business’s 50-day simple moving average is $46.99 and its 200-day simple moving average is $37.43.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business’s revenue for the quarter was up 16.9% on a year-over-year basis. Equities research analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.